Really happy to disagree with you Pete.
Minera have altered plant to accept product and want a beneficiation plant to be established solely to supply their needs. Through this they have invested in NSL.
We know BMM have placed a real order and do we also assume they have also altered their plant? It makes total sense that they would also want certainty of supply with low transport costs so why not another collaboration with NSL. Indeed why not all steel mill customers?Bear in mind we do not sell iron ore. We sell enriched ore for blending to improve existing ore product which is unique. The low grade ores we convert are not valuable so margins should not be greatly affected.
I do not believe Sam would simply buy a heap of shares an sit idly by. Their strategy is to only invest in profit making companies who pay dividends with a 5-7 year time frame. For this to happen NSL expansion would need to be accellarated. If all product is placed and in an ideal world each mill has a dedicated plant there is no risk to them. It would not surprise if they made funds available.This would be unlikely to involve shares since dilution would hurt them most.
Xinhai can handle multiple installations so it would hinge only on finance.
If only part of this happens then the whole scenario changes. I don't understand current negativity.
- Forums
- ASX - By Stock
- Ann: Plant Update - Name Plate Throughput Achieved
Really happy to disagree with you Pete. Minera have altered...
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ELE (ASX) to my watchlist
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $24.27M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEWS
Is oil undervalued?
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
ELE (ASX) Chart |
Day chart unavailable